Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
How can the risk of long-term consequences of rheumatoid arthritis be reduced?
Autore:
Pincus, T; Sokka, T;
Indirizzi:
Vanderbilt Univ, Sch Med, Div Rheumatol & Immunol, Nashville, TN 37232 USAVanderbilt Univ Nashville TN USA 37232 & Immunol, Nashville, TN 37232 USA Jyvaskyla Cent Hosp, Jyvaskyla 40620, Finland Jyvaskyla Cent Hosp Jyvaskyla Finland 40620 sp, Jyvaskyla 40620, Finland
Titolo Testata:
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
fascicolo: 1, volume: 15, anno: 2001,
pagine: 139 - 170
SICI:
1521-6942(200103)15:1<139:HCTROL>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
MODIFYING ANTIRHEUMATIC DRUG; SELF-REPORT QUESTIONNAIRES; SAWTOOTH TREATMENT STRATEGY; INTRAMUSCULAR GOLD THERAPY; PROSPECTIVE FOLLOW-UP; LOW-DOSE CYCLOSPORINE; PRELIMINARY CORE SET; 2ND LINE THERAPY; COMBINATION THERAPY; CLINICAL-TRIALS;
Keywords:
rheumatoid arthritis; treatment outcome; mortality; functional capacity; radiography;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
207
Recensione:
Indirizzi per estratti:
Indirizzo: Pincus, T Vanderbilt Univ, Sch Med, Div Rheumatol & Immunol, 203 Oxford House, Nashville, TN 37232 USA Vanderbilt Univ 203 Oxford House Nashville TN USA 37232 7232 USA
Citazione:
T. Pincus e T. Sokka, "How can the risk of long-term consequences of rheumatoid arthritis be reduced?", BEST PR R C, 15(1), 2001, pp. 139-170

Abstract

The long-term natural history of rheumatoid arthritis includes early radiographic damage and progression, severe functional declines, work disabilityand increased mortality rates. Emerging evidence suggests that this natural history may be favourably affected by disease-modifying anti-rheumatic drugs (DMARDs), which slow the radiographic progression and functional decline. it is necessary to document both the efficacy of these drugs in randomized controlled clinical trials and their long-term effectiveness in clinicalobservational studies. Although a 20% improvement in inflammatory measuresin the American College of Rheumatology Core Data Set (ACR20) distinguishes DMARDs from placebo in clinical trials, it is not clear that a control ofinflammation at this level, or even at 50%, is sufficient to prevent long-term damage. There is limited financial support for long-term observationalstudies, which depend on data from the clinical experience of rheumatologists. Quantitative databases from clinical care, can be developed to document long-term outcomes in patients with early rheumatoid arthritis to includeadditional physical, radiographic, laboratory and patient questionnaire quantitative data. Patient self-report questionnaires appear to provide the least expensive and most effective measures toward this goal.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 09:46:52